Brief: Sensorion Receives FDA'S Orphan Drug Designation For OTOF-GT

Sensorion SA

30/11/2022 06:39

Nov 30 (Reuters) - Sensorion SA  ALSEN.PA :
    * SENSORION RECEIVES ORPHAN DRUG DESIGNATION FOR OTOF-GT FOR
THE
TREATMENT OF OTOFERLIN GENE-MEDIATED HEARING LOSS FROM THE US
FOOD AND DRUG ADMINISTRATION
    * SENSORION RECEIVES ORPHAN DRUG DESIGNATION FOR OTOF-GT FOR
THE
TREATMENT OF OTOFERLIN GENE-MEDIATED HEARING LOSS FROM THE US
FOOD AND DRUG ADMINISTRATION
    * SENSORION IS ON TRACK TO FILE A CTA FOR OTOF-GT IN H1 2023
    * HAS PROGRESSED PRECLINICAL AND CLINICAL DEVELOPMENT PLANS
FOR
OTOF-GT AND IS ON TRACK TO FILE A CLINICAL TRIAL APPLICATION
(CTA) IN FIRST HALF OF 2023

Source text for Eikon:  ID:nBwbdqTnTa 
Further company coverage:  ALSEN.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))